RituxME

From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history

RituxME is a clinical trial of the rituximab ME/CFS research group at the Dept. of Oncology and Medical Physics at Haukeland University Hospital, Bergen, Norway. Senior Consultant Øystein Fluge and Professor Olav Mella are the study supervisors.[1] The final study, published in 2019, showed no overall improvement.[2]

Notable studies[edit | edit source]

Evidence[edit | edit source]

A substudy showing improvement in post-occlusive reactive hyperemia (PORH) but not Flow-Mediated Dilation (FMD) after 18 months rituximab, no changes in symptoms
  • 2019, B-Lymphocyte Depletion in Patients With Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial[2] - (Full text)
  • 2016, Serum BAFF and APRIL Levels, T-Lymphocyte Subsets, and Immunoglobulins after B-Cell Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Myalgic Encephalopathy/Chronic Fatigue Syndrome.[4] - (Full text)
  • 2015, B-Lymphocyte Depletion in Myalgic Encephalopathy/ Chronic Fatigue Syndrome. An Open-Label Phase II Study with Rituximab Maintenance Treatment[5] - (Full text)

See also[edit | edit source]

Learn more[edit | edit source]

References[edit | edit source]

  1. ↑ http://www.helse-bergen.no/en/OmOss/Avdelinger/kreft/forsking-fagutvikling/Sider/Forsking-p%C3%A5-ME.aspx
  2. ↑ 2.0 2.1 Fluge, Øystein; Rekeland, Ingrid G.; Lien, Katarina; Thürmer, Hanne; Borchgrevink, Pette C.; Schäfer, Christoph; Sørland, Kari; Aßmus, Jörg; Ktoridou-Valen, Irini; Mella, Olav (April 2, 2019). "B-Lymphocyte Depletion in Patients With Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial". Annals of Internal Medicine. doi:10.7326/M18-1451. ISSN 0003-4819.
  3. ↑ Sandvik, Miriam Kristine; Sørland, Kari; Leirgul, Elisabeth; Rekeland, Ingrid Gurvin; Stavland, Christina Særsten; Mella, Olav; Fluge, Øystein (February 2, 2023). "Endothelial dysfunction in ME/CFS patients". PLOS ONE. 18 (2): e0280942. doi:10.1371/journal.pone.0280942. ISSN 1932-6203. PMC 9894436. PMID 36730360.
  4. ↑ Lunde S, Kristoffersen EK, Sapkota D, Risa K, Dahl O, Bruland O, et al. (2016) Serum BAFF and APRIL Levels, T-Lymphocyte Subsets, and Immunoglobulins after B-Cell Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Myalgic Encephalopathy/Chronic Fatigue Syndrome. PLoS ONE 11(8): e0161226. doi:10.1371/journal.pone.0161226
  5. ↑ http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0129898
Retrieved from "https://me-pedia.org/w/index.php?title=RituxME&oldid=240843"